Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ZURA
ZURA logo

ZURA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Zura Bio Ltd (ZURA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.750
1 Day change
3.59%
52 Week Range
7.440
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Zura Bio Ltd (ZURA) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the stock has shown a slight positive price movement recently, the lack of strong technical signals, neutral insider and hedge fund activity, and no significant news or catalysts make it less compelling for immediate investment. The absence of recent congress trading data and financial performance details further limits confidence in this stock as a long-term buy.

Technical Analysis

The MACD is positive and expanding, indicating a slight bullish momentum. However, the RSI is neutral at 53.093, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key resistance levels are R1: 3.8 and R2: 3.943, while support levels are S1: 3.338 and S2: 3.195. Overall, the technical indicators suggest a mixed to slightly bearish trend.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
3

Positive Catalysts

  • The MACD is showing positive momentum, and the stock has experienced a slight price increase in the pre-market, regular market, and post-market sessions.

Neutral/Negative Catalysts

  • No significant news or event-driven catalysts. Hedge fund and insider activity are neutral. The stock's moving averages are bearish, and the RSI does not indicate a strong buy signal. Additionally, there is no recent congress trading data or financial performance insights to support a long-term investment decision.

Financial Performance

No financial performance data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for ZURA.

Wall Street analysts forecast ZURA stock price to rise
2 Analyst Rating
Wall Street analysts forecast ZURA stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.620
sliders
Low
15
Averages
16.5
High
18
Current: 3.620
sliders
Low
15
Averages
16.5
High
18
Oppenheimer
Oppenheimer
Outperform
downgrade
$16 -> $15
AI Analysis
2026-03-20
Reason
Oppenheimer
Oppenheimer
Price Target
$16 -> $15
AI Analysis
2026-03-20
downgrade
Outperform
Reason
Oppenheimer lowered the firm's price target on Zura Bio to $15 from $16 and keeps an Outperform rating on the shares after the company reported year-end financial results and highlighted progress for ongoing trials of Tibulizumab in both Hidradenitis Suppurativa and Systemic Sclerosis. The company experienced a management transition in January with co-founder Sandeep Kulkarni adding to his board role with CEO position. The firm anticipates he will be important in positioning the company for clinical execution in 2026, with the first readout late this year in HS.
Wedbush
Outperform
initiated
$15
2026-02-09
Reason
Wedbush
Price Target
$15
2026-02-09
initiated
Outperform
Reason
As previously reported, Wedbush initiated coverage of Zura Bio with an Outperform rating and $15 price target. The firm sees a favorable near- and long-term setup with shares likely to appreciate through 2026 as the market anticipates the first readout for an IL-17 combination candidate in hidradenitis suppurativa, followed by de-risked clinical readouts in the next 12-18 months.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ZURA
Unlock Now

People Also Watch